Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Captivision Inc.CAPT · Entity 9727 | Director | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Captivision Inc.
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ORDINARY SHARESSEC Table I · non-derivative | Direct | 2,599,998 |
Reported balance
After 2026-08-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 2,599,998 · Balance 2,599,998 F1: Represents 2,599,998 shares of restricted stock granted to SJ Jureller LLC, a limited liability company controlled by the Reporting Person, on August 19, 2026, under the Issuer's 2023 Incentive Award Plan, as amended, which vested in full on the grant date of August 19, 2026. The shares of restricted stock were issued for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 2,599,998 shares of restricted stock granted to SJ Jureller LLC, a limited liability company controlled by the Reporting Person, on August 19, 2026, under the Issuer's 2023 Incentive Award Plan, as amended, which vested in full on the grant date of August 19, 2026. The shares of restricted stock were issued for no consideration.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
American Renal Associates Holdings, Inc.
Report date January 25, 2021 · Filed January 26, 2021
Section 16 reporting ended · disclosed 2021-01-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-01-25 transaction · row 1
1 source rowRow 1 · 2021-01-25 · Disposition to issuer · Disposed 49,435 · Balance 0 F1: On January 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of October 1, 2020, by and among the Issuer, IRC Superman Midco, LLC ("IRC") and Superman Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger, each share of common stock of the Issuer was cancelled and converted into the right to receive $11.50 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested share of restricted stock, including performance-based restricted stock, automatically vested and was converted in the right to receive the Per Share Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of October 1, 2020, by and among the Issuer, IRC Superman Midco, LLC ("IRC") and Superman Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger, each share of common stock of the Issuer was cancelled and converted into the right to receive $11.50 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested share of restricted stock, including performance-based restricted stock, automatically vested and was converted in the right to receive the Per Share Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 20, 2026 20:00 UTC | Captivision Inc. CAPT · Entity 9727 | GrantORDINARY SHARES | 2,599,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-092087 · ownership.xml · nonDerivative · entry 1 Jureller John M · CIK 0001566300 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,599,998 F1 · balance_after: Represents 2,599,998 shares of restricted stock granted to SJ Jureller LLC, a limited liability company controlled by the Reporting Person, on August 19, 2026, under the Issuer's 2023 Incentive Award Plan, as amended, which vested in full on the grant date of August 19, 2026. The shares of restricted stock were issued for no consideration. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 17:38 UTC | American Renal Associates Holdings, Inc. ARA · Entity 143402 | Disposition to issuerCommon Stock | 49,435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-002175 · form4.xml · nonDerivative · entry 1 Jureller John M · CIK 0001566300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On January 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of October 1, 2020, by and among the Issuer, IRC Superman Midco, LLC ("IRC") and Superman Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger, each share of common stock of the Issuer was cancelled and converted into the right to receive $11.50 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested share of restricted stock, including performance-based restricted stock, automatically vested and was converted in the right to receive the Per Share Merger Consideration. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 16:11 UTC | American Renal Associates Holdings, Inc. ARA · Entity 143402 | GrantCommon Stock | 17,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001498068-20-000052 · wf-form4_158464864860245.xml · nonDerivative · entry 1 Jureller John M · CIK 0001566300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,435 F1 · kind: Reflects a grant of restricted stock that vests on March 18, 2021. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 16:08 UTC | American Renal Associates Holdings, Inc. ARA · Entity 143402 | GrantCommon Stock | 12,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001498068-19-000096 · wf-form4_157653051669146.xml · nonDerivative · entry 1 Jureller John M · CIK 0001566300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,284 F1 · kind: Reflects a grant of restricted stock that vests on March 9, 2020. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:42 UTC | American Renal Associates Holdings, Inc. ARA · Entity 143402 | GrantCommon Stock | 5,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001498068-18-000041 · wf-form4_152159294723121.xml · nonDerivative · entry 1 Jureller John M · CIK 0001566300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,526 F1 · shares: Reflects a grant of restricted stock that vests on March 19, 2019. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 17:30 UTC | American Renal Associates Holdings, Inc. ARA · Entity 143402 | GrantCommon Stock | 13,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004502 · edgar.xml · nonDerivative · entry 1 Jureller John M · CIK 0001566300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,801 F1 · kind: Reflects a grant of restricted stock that vests as follows: (a) 6,326 shares immediately vested on the grant date, March 10, 2017, and (b) 7,475 shares vest on March 10, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.